NCT00354341View on ClinicalTrials.gov

(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy

PHASE3CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Anemia
Interventions
DRUG

Epoetin beta

Trial Locations (63)

1076

Budapest

1115

Budapest

2100

Copenhagen

3526

Miskolc

4000

Roskilde

4020

Linz

7624

Pécs

9700

Szombathely

10220

Bangkok

10330

Bangkok

10400

Bangkok

11526

Athens

14000

Mexico City

15006

A Coruña

18354

Nikaia

20000

Chon Buri

20033

Desio

20092

Cinisello Balsamo

20132

Milan

20162

Milan

23900

Lecco

28007

Madrid

28046

Madrid

31238

Chihuahua City

40620

Jyväskylä

45500

Ioannina

46017

Valencia

48903

Barakaldo

48960

Galdakao

50200

Chiang Mai

54629

Thessaloniki

59100

Véria

60121

Ancona

64460

Monterrey

68100

Alexandroupoli

69115

Heidelberg

81100

Caserta

81675

München

98122

Messina

109263

Moscow

117036

Moscow

125315

Moscow

169608

Singapore

04038-002

São Paulo

586 33

Jihlava

460 63

Liberec

546 36

Thessaloniki

09100

Cagliari

15-540

Bialystok

40-027

Katowice

26 600

Radom

123 448

Moscow

08907

Barcelona

118 83

Stockholm

BT9 7LJ

Belfast

CB2 2QQ

Cambridge

E1 1BB

London

N18 1QX

London

SE22 8PT

London

TS4 3BW

Middlesbrough

M6 8HD

Salford

S57AU

Sheffield

LL13 7TD

Wrexham

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00354341 - (ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy | Biotech Hunter | Biotech Hunter